SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
Hinterlegungsschein · US82686Q1013 · SLN · A2QB4J (XNAS)
Übersicht
5,17 USD
-2,08 % -0,11 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
10.06.2025 19:59

Aktuelle Kurse von SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
SLN
USD
10.06.2025 19:59
5,17 USD
5,28 USD
-2,08 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % -5,57 % 39,73 % 14,89 % -30,04 % -75,13 % -73,49 %

Profil de l'entreprise pour SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE Certificat de dépôt

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Données de l'entreprise

Nom SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE
Société Silence Therapeutics plc
Symbole SLN
Site web https://www.silence-therapeutics.com
Marché d'origine XNAS NASDAQ
WKN A2QB4J
ISIN US82686Q1013
Type de titre Certificat de dépôt
Secteur Healthcare
Industrie Biotechnology
PDG Mr. Craig A. Tooman M.B.A.
Capitalisation boursière 149 Mio
Pays Royaume-Uni
Devise USD
Employés 0,1 T
Adresse 72 Hammersmith Road, W14 8TH London
Date d'introduction en bourse 2020-09-08

Symboles boursiers

Nom Symbole
Frankfurt XRP2.F
NASDAQ SLN

Autres actions

Les investisseurs qui détiennent SILENCE THERAPEUTICSCS PLC - AMERICAN DEPOSITORY SHARE ont également les actions suivantes dans leur portefeuille :
ABO-GROUP ENVIRONMENT
ABO-GROUP ENVIRONMENT Action
NIPPON COKE+ENGINE.CO.LTD
NIPPON COKE+ENGINE.CO.LTD Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025